Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.49 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 10/20 | 0.48 |
| ▸ | CNR2 | P34972 | 8/20 | 0.48 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5276845 | 0.98 | CNR1 (0.50) | PTGS2CYP4F2CYP4A11SMN1; SMN2CNR1 | |
| SCHEMBL229166 | 0.95 | SMN1; SMN2 (0.50) | PTGS2CYP4F2CYP4A11SMN1; SMN2CNR1 | |
| SCHEMBL10296729 | 0.93 | PTGS2 (0.47) | PTGS2CYP4F2CYP4A11SMN1; SMN2CNR1 | |
| SCHEMBL22340197 | 0.90 | PTGS2 (0.44) | PTGS2CYP4F2CYP4A11SMN1; SMN2CNR1 | |
| SCHEMBL63490 | 0.89 | CYP4F2 (0.56) | CYP4F2CYP4A11SMN1; SMN2CYP4Z1ALOX5 | |
| SCHEMBL1206811 | 0.85 | HDAC1 (0.64) | CYP4F2CYP4A11PPARGPPARAHDAC1 | |
| SCHEMBL22340234 | 0.85 | ALOX5 (0.43) | PTGS2CYP4F2CYP4A11SMN1; SMN2CYP4Z1 | |
| SCHEMBL7999711 | 0.84 | ALOX5 (0.59) | CYP4F2CYP4A11CYP4Z1ALOX5 | |
| SCHEMBL17274751 | 0.84 | HDAC1 (0.66) | PPARGPPARAHDAC1HDAC6 | |
| SCHEMBL3675681 | 0.83 | ALOX5 (0.57) | CYP4F2CYP4A11CYP4Z1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172339-A1 | ANGIOGENIC RESORCINOL DERIVATIVES | NORTHEASTERN UNIVERSITY (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120172339-A1 | ANGIOGENIC RESORCINOL DERIVATIVES | NORTHEASTERN UNIVERSITY (US) | 2012-07-05 | — | — | US | disclosed |
| WO-2011006099-A1 | ANGIOGENIC RESORCINOL DERIVATIVES | NORTHEASTERN UNIVERSITY (US) | 2011-01-13 | — | — | WO | disclosed |
| WO-2011006099-A1 | ANGIOGENIC RESORCINOL DERIVATIVES | NORTHEASTERN UNIVERSITY (US) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172339-A1 | ANGIOGENIC RESORCINOL DERIVATIVES | CNR1, CNR2, KDR | PTGS2 587/4885CYP4F2 1209/4885CYP4A11 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.